Drug Type Monoclonal antibody |
Synonyms LM 102, LM102 |
Target |
Mechanism CLDN18.2 inhibitors(Claudin 18.2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 2 | CN | 06 Oct 2021 | |
CLDN18.2 positive Solid Tumors | Phase 2 | CN | 06 Oct 2021 | |
Solid tumor | Phase 1 | CN | 30 Jan 2022 | |
Bile Duct Neoplasms | IND Approval | CN | 27 Oct 2022 | |
Pancreatic Cancer | IND Approval | CN | 27 Oct 2022 | |
Stomach Cancer | IND Approval | CN | 27 Oct 2022 |